Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF417 (ImmuneEditome ID:147687)

1. Gene summary of enriched editing regions for ZNF417

Gene summary

Gene information	Gene symbol	ZNF417
	Gene ID	147687
	GeneSynonyms	-
	GeneCytomap	19q13.43
	GeneType	protein-coding
	GeneDescription	zinc finger protein 417
	GeneModificationdate	20230518
	UniprotID	Q8TAU3;M0R230;M0R178;M0R0M6;M0R0V5
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr19:57902679-57903000:-	ENST00000594396.1	ENSG00000173480.9	ZNF417	intronic	AluY,HERVK14-int	chr19:57902679-57903000:-.alignment
chr19:57904757-57907173:-	ENST00000312026.5	ENSG00000173480.9	ZNF417	UTR3	AluSp,AluSx1,U2,AluSq2,AluSz6,AluSg7	chr19:57904757-57907173:-.alignment

Top

2. Tumor-specific enriched editing regions for ZNF417

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
ENSG00000173480.9,ZNF417	BRCA	EAG	2.1551e-02
chr19:57904757-57907173:-	LUSC	EER	7.8774e-03
ENSG00000173480.9,ZNF417	LUSC	EAG	2.4090e-03
chr19:57902679-57903000:-	THCA	EER	7.4861e-04
chr19:57904757-57907173:-	THCA	EER	3.7997e-02
ENSG00000173480.9,ZNF417	THCA	EAG	1.1538e-03

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000173480.9,ZNF417	BLCA	Path	EAG	1.6893e-02	1.7552e-02	0.1649
chr19:57904757-57907173:-	CESC	Cli	EER	3.6931e-02	8.8489e-03	0.2927

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
ENSG00000173480.9,ZNF417	GBM	EAG	3.6847e-02	1.7041e-02	1.4442e+01

Top

3. Enriched editing regions and immune related genes for ZNF417

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr19:57904757-57907173:-

GBM

EER

ENSG00000167595,PROSER3

-0.4836

6.1178e-06

3.0042e-07

-0.4182

BCCIP;BUD13;CSTF2T;ELAVL1;FAM120A;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS1;KHSRP;LIN28B;NONO;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2

Monocytes

GSVA_HALLMARK_FATTY_ACID_METABOLISM

chr19:57904757-57907173:-

GBM

EER

ENSG00000278129,ZNF8

-0.4695

1.4189e-05

1.5175e-07

-0.4276

BCCIP;BUD13;CSTF2T;ELAVL1;FAM120A;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP3;KHSRP;LIN28B;NONO;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2

Monocytes

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr19:57904757-57907173:-

GBM

EER

ENSG00000168916,ZNF608

-0.4630

2.1728e-05

2.7849e-07

-0.4193

CSTF2T;ELAVL1;HNRNPA1;HNRNPA2B1;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS1;KHSRP;LIN28B;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SAFB2;SRSF1;TAF15;TARDBP;U2AF2

Monocytes

GSVA_HALLMARK_MITOTIC_SPINDLE

chr19:57904757-57907173:-

GBM

EER

ENSG00000198182,ZNF607

-0.4610

2.7170e-05

6.1144e-07

-0.4082

BCCIP;BUD13;CSTF2T;ELAVL1;FAM120A;HNRNPA1;HNRNPA2B1;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS1;KHSRP;LIN28B;NONO;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2

Monocytes

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr19:57904757-57907173:-

GBM

EER

ENSG00000196235,SUPT5H

-0.4530

4.1317e-05

8.3833e-07

-0.4036

BCCIP;BUD13;CSTF2T;ELAVL1;FAM120A;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS1;KHSRP;LIN28B;NONO;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2

Monocytes

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr19:57904757-57907173:-

GBM

EER

ENSG00000249115,HAUS5

-0.4484

4.8683e-05

1.0170e-06

-0.4007

Monocytes

GSVA_HALLMARK_KRAS_SIGNALING_UP

chr19:57904757-57907173:-

GBM

EER

ENSG00000173480,ZNF417

-0.4428

6.7453e-05

8.7013e-07

-0.4030

Monocytes

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr19:57904757-57907173:-

GBM

EER

ENSG00000171456,ASXL1

-0.4425

6.8656e-05

4.9322e-07

-0.4112

Monocytes

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

chr19:57904757-57907173:-

GBM

EER

ENSG00000186017,ZNF566

-0.4397

7.3050e-05

6.0829e-07

-0.4082

Monocytes

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

chr19:57904757-57907173:-

GBM

EER

ENSG00000129351,ILF3

-0.4406

7.7495e-05

6.5026e-07

-0.4073

ILF3

Monocytes

GSVA_HALLMARK_XENOBIOTIC_METABOLISM

More results

Top

4. Enriched editing regions and immune related splicing for ZNF417

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr19:57904757-57907173:-

ESCA

EER

ENSG00000136485.10

chr17

63588999:63589237:63594202:63594259

-0.4410

6.4062e-04

5.1487e-10

-0.4814

T_cells_CD4_memory_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

chr19:57904757-57907173:-

ESCA

EER

ENSG00000196712.12

chr17

31258343:31258502:31248983:31249119:31248983:31253000

-0.4303

6.7135e-04

1.5828e-07

-0.4162

NF1

T_cells_CD4_memory_resting

GSVA_HALLMARK_BILE_ACID_METABOLISM

chr19:57904757-57907173:-

ESCA

EER

ENSG00000055950.12

chr10

100981375:100983817:100983947:100984074

-0.3508

1.1042e-02

5.0643e-07

-0.4109

BUD13;CSTF2T;ELAVL1;FAM120A;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS1;LIN28B;NONO;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_BILE_ACID_METABOLISM

chr19:57904757-57907173:-

ESCA

EER

ENSG00000147894.10

chr9

27558490:27560299:27561584:27561649

0.3427

1.3792e-02

1.2929e-06

0.4012

BUD13;CSTF2T;ELAVL1;HNRNPA1;HNRNPA2B1;HNRNPM;HNRNPU;IGF2BP3;KHDRBS1;KHSRP;LIN28B;NOP56;NOP58;PRPF8;RBFOX2;RBM10;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2

T_cells_CD4_memory_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr19:57904757-57907173:-

ESCA

EER

ENSG00000182872.11

chrX

47173127:47173197:47176499:47176586

-0.3862

8.2205e-04

3.3298e-07

-0.4393

BCCIP;BUD13;CSTF2T;ELAVL1;FAM120A;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS1;KHSRP;LIN28B;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SF3A3;SF3B4;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2

T_cells_CD4_memory_resting

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

chr19:57904757-57907173:-

ESCA

EER

ENSG00000261915.2

chr17

7317460:7317932:7318064:7318172

0.4125

1.9092e-03

1.8813e-08

0.4433

BCCIP;BUD13;CSTF2T;ELAVL1;FAM120A;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP3;KHDRBS1;KHSRP;LIN28B;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2

Neutrophils

GSVA_HALLMARK_PEROXISOME

chr19:57904757-57907173:-

ESCA

EER

ENSG00000173821.15

chr17

80379417:80379714:80380832:80380891

0.2591

1.5102e-02

1.7326e-06

0.4222

GSVA_HALLMARK_PROTEIN_SECRETION

chr19:57904757-57907173:-

ESCA

EER

ENSG00000217128.7

chr5

131709200:131709272:131710577:131710661:131716564:131716656

-0.3305

2.2524e-02

7.9154e-07

-0.4114

BCCIP;BUD13;CSTF2T;ELAVL1;FAM120A;GTF2F1;HNRNPA1;HNRNPM;HNRNPU;IGF2BP3;KHDRBS1;KHSRP;LIN28B;NONO;NOP56;NOP58;PCBP2;PRPF8;RBFOX2;RBM10;SF3A3;SF3B4;SRSF1;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2

NK_cells_resting

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

chr19:57904757-57907173:-

ESCA

EER

ENSG00000132612.14

chr16

69321210:69322700:69324207:69325042

-0.4423

5.6526e-04

3.4923e-08

-0.4330

VPS4A

T_cells_CD4_memory_resting

GSVA_HALLMARK_HYPOXIA

chr19:57904757-57907173:-

EER

MEX

ENSG00000174227.11

chr4

516069:516185:521055:521302:523458:523913:527038:527230

-0.3402

8.5765e-05

6.6870e-11

-0.4158

Eosinophils

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results

Top

5. Enriched editing regions and immune infiltration for ZNF417

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
ENSG00000173480.9,ZNF417	ACC	EAG	Plasma_cells	4.2015e-02	0.4370
chr19:57902679-57903000:-	BLCA	EER	Mast_cells_resting	2.0907e-03	-0.2891
chr19:57904757-57907173:-	BLCA	EER	Macrophages_M0	1.4355e-02	-0.1807
ENSG00000173480.9,ZNF417	BLCA	EAG	T_cells_gamma_delta	4.0891e-02	-0.1426
chr19:57904757-57907173:-	BRCA	EER	T_cells_regulatory_(Tregs)	2.9247e-03	0.1021
ENSG00000173480.9,ZNF417	BRCA	EAG	T_cells_regulatory_(Tregs)	5.2757e-03	0.0929
chr19:57904757-57907173:-	ESCA	EER	T_cells_CD4_naive	1.9066e-05	0.3425
ENSG00000173480.9,ZNF417	ESCA	EAG	T_cells_CD4_memory_resting	2.1878e-03	-0.2475
chr19:57904757-57907173:-	GBM	EER	Monocytes	6.2001e-05	0.3330
ENSG00000173480.9,ZNF417	GBM	EAG	Monocytes	3.4961e-03	0.2435
ENSG00000173480.9,ZNF417	HNSC	EAG	T_cells_CD4_memory_resting	3.7782e-02	0.1899
ENSG00000173480.9,ZNF417	KICH	EAG	Mast_cells_resting	6.0357e-03	0.3831
chr19:57904757-57907173:-	KIRC	EER	T_cells_gamma_delta	2.9850e-05	0.2573
ENSG00000173480.9,ZNF417	KIRC	EAG	T_cells_gamma_delta	1.0361e-03	0.1997
chr19:57904757-57907173:-	LAML	EER	T_cells_CD8	7.9608e-03	-0.2912
ENSG00000173480.9,ZNF417	LAML	EAG	T_cells_CD8	1.0215e-02	-0.2597
chr19:57902679-57903000:-	LGG	EER	T_cells_CD4_naive	1.6954e-02	0.1537
chr19:57904757-57907173:-	LGG	EER	T_cells_follicular_helper	2.1545e-02	0.1246
ENSG00000173480.9,ZNF417	LGG	EAG	T_cells_CD4_naive	5.0773e-04	0.1768
chr19:57904757-57907173:-	LIHC	EER	Macrophages_M2	9.7366e-03	-0.4800
ENSG00000173480.9,ZNF417	LIHC	EAG	T_cells_follicular_helper	4.0355e-02	0.3386
chr19:57904757-57907173:-	LUAD	EER	T_cells_regulatory_(Tregs)	3.7409e-04	0.2065
ENSG00000173480.9,ZNF417	LUAD	EAG	T_cells_regulatory_(Tregs)	8.1940e-05	0.2197
chr19:57904757-57907173:-	LUSC	EER	Mast_cells_resting	7.1417e-03	-0.1634
ENSG00000173480.9,ZNF417	LUSC	EAG	Mast_cells_resting	3.5976e-03	-0.1673
ENSG00000173480.9,ZNF417	MESO	EAG	NK_cells_resting	1.8663e-02	0.4013
chr19:57904757-57907173:-	OV	EER	Macrophages_M2	7.7385e-03	-0.1748
ENSG00000173480.9,ZNF417	OV	EAG	T_cells_CD8	1.2589e-03	0.1982
chr19:57904757-57907173:-	PAAD	EER	T_cells_CD4_memory_resting	7.8776e-04	0.3724
ENSG00000173480.9,ZNF417	PAAD	EAG	T_cells_CD4_memory_resting	1.3689e-03	0.3398
chr19:57904757-57907173:-	PCPG	EER	T_cells_gamma_delta	1.4143e-04	0.3751
ENSG00000173480.9,ZNF417	PCPG	EAG	T_cells_CD4_memory_activated	1.5250e-02	0.2258
chr19:57904757-57907173:-	PRAD	EER	T_cells_CD4_memory_activated	1.7523e-02	0.1234
ENSG00000173480.9,ZNF417	READ	EAG	Macrophages_M1	2.0248e-02	0.3571
chr19:57904757-57907173:-	SARC	EER	Monocytes	8.2821e-03	0.2737
ENSG00000173480.9,ZNF417	SARC	EAG	B_cells_memory	4.0771e-02	-0.1963
chr19:57904757-57907173:-	SKCM	EER	Plasma_cells	1.8201e-02	-0.1566
ENSG00000173480.9,ZNF417	SKCM	EAG	Plasma_cells	1.4529e-02	-0.1511
chr19:57904757-57907173:-	STAD	EER	Macrophages_M2	3.5121e-02	-0.1223
ENSG00000173480.9,ZNF417	STAD	EAG	Eosinophils	1.5431e-02	-0.1377
chr19:57904757-57907173:-	TGCT	EER	B_cells_memory	1.3818e-02	-0.2171
ENSG00000173480.9,ZNF417	TGCT	EAG	B_cells_memory	1.1757e-02	-0.2212
chr19:57902679-57903000:-	THCA	EER	Neutrophils	7.0709e-03	0.1452
chr19:57904757-57907173:-	THCA	EER	Neutrophils	4.7132e-02	-0.1037
ENSG00000173480.9,ZNF417	THCA	EAG	NK_cells_activated	2.5489e-02	-0.1097
chr19:57902679-57903000:-	THYM	EER	Monocytes	9.4493e-03	-0.3567
chr19:57904757-57907173:-	UCEC	EER	Dendritic_cells_resting	4.1527e-02	0.2409
ENSG00000173480.9,ZNF417	UCEC	EAG	Macrophages_M1	3.3587e-02	-0.2308
ENSG00000173480.9,ZNF417	UCS	EAG	T_cells_gamma_delta	3.8594e-03	0.5116

Top

6. Enriched editing regions and immune gene sets for ZNF417

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
ENSG00000173480.9,ZNF417	LUAD	EAG	6.6098e-03	0.1525	4.3726e-02	0.1135	2.1547e-02	0.1293	4.0811e-02	0.1151
chr19:57904757-57907173:-	PCPG	EER	3.5341e-03	-0.2920	4.6778e-03	-0.2835	4.4437e-03	-0.2850	3.6001e-02	-0.2121

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr19:57904757-57907173:-	BLCA	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	3.3988e-02	0.1568
ENSG00000173480.9,ZNF417	BLCA	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	1.4804e-02	0.1696
chr19:57904757-57907173:-	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.0651e-11	0.2274
ENSG00000173480.9,ZNF417	BRCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	4.0449e-10	0.2063
ENSG00000173480.9,ZNF417	CESC	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	3.7399e-02	0.2106
chr19:57904757-57907173:-	CESC	GSVA_HALLMARK_COAGULATION	EER	1.8170e-02	0.2619
ENSG00000173480.9,ZNF417	CHOL	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	4.7597e-02	0.4480
ENSG00000173480.9,ZNF417	COAD	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	9.3965e-03	0.2288
chr19:57904757-57907173:-	COAD	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.8567e-02	0.2034
ENSG00000173480.9,ZNF417	ESCA	GSVA_HALLMARK_P53_PATHWAY	EAG	1.9883e-03	0.2497
chr19:57904757-57907173:-	ESCA	GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION	EER	7.3531e-04	0.2736
chr19:57904757-57907173:-	GBM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.1044e-06	0.3898
ENSG00000173480.9,ZNF417	GBM	GSVA_HALLMARK_KRAS_SIGNALING_UP	EAG	1.1312e-04	0.3183
ENSG00000173480.9,ZNF417	HNSC	GSVA_HALLMARK_GLYCOLYSIS	EAG	1.8003e-02	0.2156
ENSG00000173480.9,ZNF417	KICH	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EAG	1.3293e-02	-0.3479
ENSG00000173480.9,ZNF417	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	4.0703e-03	-0.1753
chr19:57904757-57907173:-	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	8.7840e-04	-0.2063
chr19:57904757-57907173:-	KIRP	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.7905e-02	0.2264
ENSG00000173480.9,ZNF417	LAML	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	4.6737e-02	-0.2025
chr19:57904757-57907173:-	LAML	GSVA_HALLMARK_ADIPOGENESIS	EER	1.7981e-02	0.2608
ENSG00000173480.9,ZNF417	LGG	GSVA_HALLMARK_SPERMATOGENESIS	EAG	4.9593e-02	0.1004
ENSG00000173480.9,ZNF417	LUAD	GSVA_HALLMARK_GLYCOLYSIS	EAG	1.0244e-03	0.1839
chr19:57902679-57903000:-	LUAD	GSVA_HALLMARK_GLYCOLYSIS	EER	2.3400e-02	0.1748
chr19:57904757-57907173:-	LUAD	GSVA_HALLMARK_MYC_TARGETS_V2	EER	2.1944e-03	0.1782
chr19:57904757-57907173:-	LUSC	GSVA_HALLMARK_MYC_TARGETS_V1	EER	1.1661e-05	0.2633
ENSG00000173480.9,ZNF417	LUSC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	2.1531e-03	-0.1762
chr19:57904757-57907173:-	OV	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	2.4356e-06	-0.3044
ENSG00000173480.9,ZNF417	OV	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.8070e-04	-0.2227
chr19:57904757-57907173:-	PAAD	GSVA_HALLMARK_COAGULATION	EER	4.9534e-02	0.2232
ENSG00000173480.9,ZNF417	PAAD	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	2.6438e-02	0.2394
ENSG00000173480.9,ZNF417	PCPG	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	5.0991e-03	-0.2595
chr19:57904757-57907173:-	PCPG	GSVA_HALLMARK_GLYCOLYSIS	EER	4.0653e-04	-0.3503
chr19:57904757-57907173:-	PRAD	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.7342e-05	-0.2213
ENSG00000173480.9,ZNF417	PRAD	GSVA_HALLMARK_APICAL_SURFACE	EAG	8.7514e-03	-0.1314
ENSG00000173480.9,ZNF417	READ	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	3.3653e-02	-0.3285
chr19:57904757-57907173:-	SARC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.8991e-03	0.3196
ENSG00000173480.9,ZNF417	SARC	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	1.0774e-02	0.2434
chr19:57904757-57907173:-	SKCM	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	2.6764e-02	0.1470
ENSG00000173480.9,ZNF417	STAD	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	1.6554e-03	0.1782
chr19:57904757-57907173:-	STAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.4300e-03	0.1842
chr19:57902679-57903000:-	TGCT	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.1402e-02	0.3516
chr19:57904757-57907173:-	TGCT	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	6.8172e-04	0.2964
ENSG00000173480.9,ZNF417	TGCT	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	1.4609e-03	0.2774
chr19:57904757-57907173:-	THCA	GSVA_HALLMARK_SPERMATOGENESIS	EER	1.1923e-02	-0.1311
ENSG00000173480.9,ZNF417	THCA	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	1.8242e-02	-0.1158
chr19:57902679-57903000:-	THCA	GSVA_HALLMARK_PEROXISOME	EER	3.8691e-02	0.1117
chr19:57904757-57907173:-	UCEC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.2740e-02	-0.2682
ENSG00000173480.9,ZNF417	UCS	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	4.1174e-02	0.3750

Top

7. Enriched editing regions and drugs for ZNF417

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr19:57904757-57907173:-	BLCA	JW.7.52.1	EER	4.7817e-04	-0.2556
ENSG00000173480.9,ZNF417	BLCA	CGP.60474	EAG	2.1702e-03	-0.2125
chr19:57902679-57903000:-	BLCA	Docetaxel	EER	5.3103e-03	-0.2629
chr19:57904757-57907173:-	BRCA	CCT007093	EER	1.7004e-09	0.2050
ENSG00000173480.9,ZNF417	BRCA	CCT007093	EAG	1.1897e-06	0.1610
chr19:57904757-57907173:-	CESC	ATRA	EER	6.7085e-03	0.2989
ENSG00000173480.9,ZNF417	CESC	BX.795	EAG	1.2879e-02	0.2504
ENSG00000173480.9,ZNF417	COAD	ABT.263	EAG	3.8760e-03	0.2536
chr19:57904757-57907173:-	COAD	Midostaurin	EER	2.3209e-03	0.2801
chr19:57904757-57907173:-	ESCA	AMG.706	EER	5.1405e-06	-0.3648
ENSG00000173480.9,ZNF417	ESCA	CGP.60474	EAG	1.4369e-04	-0.3045
chr19:57904757-57907173:-	GBM	GNF.2	EER	5.8779e-06	-0.3737
ENSG00000173480.9,ZNF417	GBM	GNF.2	EAG	8.2320e-04	-0.2776
ENSG00000173480.9,ZNF417	HNSC	AZD.0530	EAG	1.7157e-02	0.2172
ENSG00000173480.9,ZNF417	KICH	KU.55933	EAG	1.5546e-02	0.3405
ENSG00000173480.9,ZNF417	KIRC	AS601245	EAG	2.0182e-03	0.1882
chr19:57904757-57907173:-	KIRC	Imatinib	EER	8.6525e-04	0.2066
ENSG00000173480.9,ZNF417	KIRP	Dasatinib	EAG	2.2067e-03	-0.2746
chr19:57904757-57907173:-	KIRP	Dasatinib	EER	9.6123e-04	-0.3119
ENSG00000173480.9,ZNF417	LAML	Embelin	EAG	1.3691e-03	0.3206
chr19:57904757-57907173:-	LAML	Embelin	EER	8.6015e-05	0.4199
ENSG00000173480.9,ZNF417	LGG	AP.24534	EAG	2.4402e-02	0.1150
chr19:57904757-57907173:-	LUAD	CCT007093	EER	1.7993e-02	0.1381
ENSG00000173480.9,ZNF417	LUAD	CCT007093	EAG	5.9958e-03	0.1543
chr19:57902679-57903000:-	LUAD	Axitinib	EER	1.0464e-03	0.2507
chr19:57904757-57907173:-	LUSC	AZD6482	EER	1.0170e-05	0.2650
ENSG00000173480.9,ZNF417	LUSC	AP.24534	EAG	1.2708e-04	0.2191
ENSG00000173480.9,ZNF417	MESO	AZD.2281	EAG	3.3991e-04	-0.5784
chr19:57904757-57907173:-	OV	BMS.509744	EER	1.3856e-08	-0.3626
ENSG00000173480.9,ZNF417	OV	CEP.701	EAG	2.0962e-08	-0.3376
chr19:57904757-57907173:-	PAAD	GSK269962A	EER	6.3461e-03	-0.3125
ENSG00000173480.9,ZNF417	PAAD	BIRB.0796	EAG	1.5260e-02	0.2609
chr19:57904757-57907173:-	PCPG	CCT007093	EER	2.2634e-02	-0.2301
ENSG00000173480.9,ZNF417	PCPG	GW843682X	EAG	1.5388e-02	0.2255
chr19:57904757-57907173:-	PRAD	CCT018159	EER	2.6301e-05	0.2166
ENSG00000173480.9,ZNF417	PRAD	CCT018159	EAG	1.3424e-03	0.1604
ENSG00000173480.9,ZNF417	READ	CGP.082996	EAG	1.0452e-02	0.3910
ENSG00000173480.9,ZNF417	SARC	FH535	EAG	2.1662e-03	0.2907
chr19:57902679-57903000:-	SARC	JNK.9L	EER	9.4690e-03	0.3103
chr19:57904757-57907173:-	SARC	JNJ.26854165	EER	3.5812e-03	0.3007
chr19:57904757-57907173:-	SKCM	AZD.0530	EER	2.0384e-02	0.1539
ENSG00000173480.9,ZNF417	SKCM	Epothilone.B	EAG	8.0367e-03	0.1637
chr19:57904757-57907173:-	STAD	AP.24534	EER	4.7312e-05	0.2338
ENSG00000173480.9,ZNF417	STAD	Bleomycin	EAG	2.5466e-04	-0.2067
chr19:57902679-57903000:-	TGCT	FH535	EER	3.4335e-02	-0.2970
chr19:57904757-57907173:-	TGCT	AZD7762	EER	8.1906e-04	-0.2922
ENSG00000173480.9,ZNF417	TGCT	BMS.708163	EAG	1.0477e-03	-0.2853
chr19:57904757-57907173:-	THCA	BAY.61.3606	EER	1.2207e-02	0.1307
ENSG00000173480.9,ZNF417	THCA	CCT018159	EAG	1.0213e-02	0.1260
chr19:57902679-57903000:-	THYM	AUY922	EER	8.6088e-03	0.3607
chr19:57904757-57907173:-	UCEC	ATRA	EER	3.5375e-04	0.4096
ENSG00000173480.9,ZNF417	UCEC	JNK.Inhibitor.VIII	EAG	7.3038e-04	0.3594
ENSG00000173480.9,ZNF417	UCS	Methotrexate	EAG	1.6635e-03	-0.5494

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType